NeuroSearch A/S
Pederstrupvej 93
DK-2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

NeuroSearch A/S – Interim report for Q1 2009

The Board of Directors of NeuroSearch A/S today considered and adopted the company's interim report for the period 1 January to 31 March 2009.

The financial result for the period was a loss before financials and other shares of results of DKK 96.7 million (a loss of DKK 86.5 million in the same period of 2008).

NeuroSearch retains its financial guidance for the full year 2009, expecting a loss before financials and other shares of results in the region of DKK 350 million.

The company's capital resources totalled DKK 550.7 million at 31 March 2009 (DKK 823.5 million at 31 March 2008). These financial resources together with research revenues from existing partners are expected to be sufficient to fund NeuroSearch's drug discovery and drug development activities until the end of 2010 assuming that no new licence agreements are entered into and that no milestone payments are received.

Key events in Q1 2009 and the subsequent period:

- ACR16 – Huntington's disease: Successful completion of the patient recruitment in the European Phase III study, MermaiHD.

  In February 2009, NeuroSearch regained all commercial rights to ACR16, including worldwide rights for the treatment of Huntington's disease.

- Tesofensine – obesity: Confirmation from the FDA regarding an End of Phase II meeting and with an agreed meeting date in the second quarter of 2009.

- Development alliance with GSK: Expansion of the portfolio of development candidates under the alliance collaboration, potentially leading to milestone payments to NeuroSearch of a total of up to more than DKK 6 billion (more than EUR 805 million) plus double-digit royalties on GSK's global sales of any marketed product from the collaboration. In addition, NeuroSearch holds a conditional share put option to sell shares to GSK totalling up to DKK 149 million (EUR 20 million).

- Discovery and development alliance with Eli Lilly (Lilly): New three-year drug discovery and development alliance with Lilly under which NeuroSearch has received DKK 29.5 million (USD 5 million) in cash payment and issued new shares to the amount of DKK 99.2 million (USD 17 million) to Lilly at a price of DKK 187 per share. In addition, NeuroSearch will receive research funding of DKK 45.0 million (USD 8 million) plus substantial milestone payments and sales royalties on new products developed under the alliance.

- ACR343 – schizophrenia: Successful completion of clinical Phase I studies with ACR343. NeuroSearch expects to continue the clinical development of the product for the treatment of schizophrenia.

- Phase II results with ABT-894 under development for neuropathic pain in collaboration with Abbott showed that ABT-894 is safe and well-tolerated but without sufficient effect on pain reduction to support the further development in this indication. ABT-894 is also

in development for the treatment of ADHD. Phase II results with NS2359 for the treatment of depression in collaboration with GSK also did neither demonstrate sufficient effect to support the further development.

In connection with the announcement of the Q1 report for 2009, Flemming Pedersen, CEO of NeuroSearch, comments:

"During the first months of the year we have reached important milestones. With the completion of the patient recruitment in our European Phase III study with ACR16 for the treatment of Huntington's disease we have moved an important step closer to our aim of bringing our first product to the market. By entering new drug discovery and development agreements with international pharmaceutical companies, we have strengthened our capital resources and the basis for bringing new products into our pipeline."

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4460 8212 or +45 4017 5103

Presentation of the Q1 Report 2009

The Q1 2009 report will be reviewed at NeuroSearch's Annual General Meeting, which will be held today at 4.00 pm at the Radisson SAS Falconer Hotel.

NeuroSearch - Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK) and a license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase I), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

Q1 Report 2009

MANAGEMENT'S REPORT

Drug pipeline

NeuroSearch's pipeline comprises 12 drug candidates that have all been generated through the company's own research and development. Of the 12 programmes, seven are in clinical development (Phases I-III) and five in preclinical phase with a view to initiating clinical studies during 2009 and the first part of 2010.

Indication	Programme	Mechanism	Partner	PC dev.	Phase I	Phase II	Phase III	NDA / Reg.
Huntington's disease	ACR16	Dopaminergic stabil.						
Obesity	Tesofensine	MRI						
ADHD	ABT-894	NNR modulator	Abbott					
Dyskinesias (PD)	ACR325	Dopaminergic stabil.						
Schizophrenia	ACR343	Dopaminergic stabil.						
Cognitive dysfunctions	ABT-560	NNR modulator	Abbott					
Anxiety	NSD-788	MRI						
Pain	NSD-721	GABA modulator	GSK					
Schizophrenia	NSD-761	Ion channel mod.	GSK					
Autoimmune diseases	NSD-726	Ion channel mod.	GSK					
Psychosis	NSD-847	Dopaminergic stabil.	GSK					
ADHD	NSD-867	Cortical enhancer	GSK					

<u>ACR16 – Huntington's disease: In pivotal clinical Phase III</u>

ACR16 is a doperminergic stabiliser which NeuroSearch is evaluating in a clinical Phase III programme with the aim of registering and marketing the product as a novel and specific treatment of Huntington's disease. ACR16 represents a novel class of drug candidates with a unique mechanism of action and in several studies the compound has demonstrated highly promising effects on a number of severe symptoms related to the disease.

NeuroSearch holds all rights to ACR16, which has received "Orphan Drug" designation from the health authorities in both the United States and Europe. The goal is to complete the development of ACR16 as quickly as possible and bring the product to the patients.

The ongoing Phase III programme comprises two studies to evaluate the efficacy and safety of ACR16 within Huntington's disease: MermaiHD, a European multicenter Phase III study, and HART, a multicenter Phase IIb study which is being carried out in North America.

End of March this year, NeuroSearch successfully completed the recruitment of patients for MermaidHD less than a year after the first patient was enrolled for the study. With well over 420 patients enrolled, MermaiHD is the biggest Huntington's disease study which has ever been performed in Europe. To date, 99% of the patients who have completed the 26 weeks of treatment in MermaiHD have chosen to continue their treatment in a six month, open-label extension study, and further the first patients have now completed 12 months' treatment with ACR16. So far, the safety profile of ACR16 has shown to be very satisfactory. The results from MermaiHD are expected to be available by the end of 2009.

The HART study is expected to enrol up to 220 Huntington patients in about 25 centres in the United States and Canada. The recruitment of patients to the HART study is progressing according to plan and is expected to be completed later in 2009. Results will be available in the beginning of 2010.

NeuroSearch considers ACR16 to be a highly attractive product opportunity, based on an assessment of the commercial potential within Huntington's disease. The estimated total number of patients suffering from Huntington's disease worldwide is approximately 100,000, and no effective treatment for the disease is currently available. ACR16 is one of the only new drugs in late-stage development for Huntington's disease, and NeuroSearch's management estimates that in future ACR16 can form the basis of sizeable revenue and earnings.

With a view to in house launching and marketing of ACR16 after registration, which is expected in 2011, NeuroSearch has begun building up an in house sales and marketing organisation.

Tesofensine – obesity: Ready for pivotal clinical Phase III

Tesofensine is a monoamine reuptake inhibitor which NeuroSearch has evaluated in Phase II studies with unique effect for the treatment of obesity. After six months of treatment, a weight loss of approx. 10% was obtained (TIPO-1) and a weight loss of approx. 13% was seen after 12 months of treatment (TIPO-4). NeuroSearch believes that these results make tesofensine one of the most effective anti-obesity products in late-stage development.

The results from TIPO-1 were published in October 2008 in the highly reputed international scientific journal The Lancet with the conclusions that tesofensine can produce a weight loss at least twice that of currently approved anti-obesity drugs and that it should be further evaluated Phase III studies in order to prepare for market registration.

NeuroSearch has built up a substantial data package supporting the strong profile of tesofensine. This includes safety data from more than 1,400 individuals having received treatment with tesofensine and of these approx. 1,200 individuals have received relevant therapeutic doses.

In March 2009, NeuroSearch obtained confirmation regarding an End of Phase II meeting with the FDA on tesofensine for the treatment of obesity, and a meeting date in the second quarter of 2009 has been agreed upon. All available data and the planned Phase III development programme will now be discussed with the FDA, and NeuroSearch also prepares for meetings later in 2009 with the European health authorities EMEA.

After the regulatory interactions, NeuroSearch will finally decide on the pivotal Phase III programme, which should lead to product registration and marketing authorisation, and on the strategy for final development of the drug.

Medical treatment of obesity is predominantly handled through general practitioners, and the marketing of tesofensine would thus require a sizeable sales force. In accordance with NeuroSearch's strategy within major disease areas, it is our intention to enter into a collaborative agreement with an international pharmaceutical company at a suitable point in time.

Licence collaboration with Abbott within NNR modulators:

ABT-894 – ADHD and ABT-560 – cognitive dysfunctions

The drug candidates ABT-894 and ABT-560 are in clinical development under a licence agreement with Abbott. Under the terms of the agreement, Abbott is responsible for and finances all clinical development, production and marketing of products under the collaboration and NeuroSearch is eligible to receive milestone payments and royalties on Abbott's global sales.

Q1 Report 2009

ABT-894 is an α4β2 subtype-specific NNR agonist which Abbott has evaluated with a positive result in a Phase II clinical study for the treatment of adults suffering from ADHD. The results reported in June 2008 showed that treatment with ABT-894 led to a statistically significant improvement in the symptoms of adult patients, and ABT-894 also proved to be safe and generally well-tolerated.

ABT-560 is also an α4β2 subtype-specific NNR agonist which Abbott has evaluated in Phase I studies with a view to developing this drug candidate for the treatment of cognitive disorders related to various CNS disorders, focusing especially on Alzheimer's disease as well as cognitive disorders related to schizophrenia.

ACR325 – Dyskinesias in Parkinson's disease: In clinical Phase I

ACR325 is a dopaminergic stabiliser, which in accordance with NeuroSearch's goal of building up a portfolio of specialist drugs, is being developed with a focus on the treatment of dyskinesias (involuntary movements) in Parkinson patients. Dyskinesias arise with a large number of patients with Parkinson's disease following long-term treatment with L-Dopa, which is the standard treatment. ACR325 has shown highly promising preclinical results within the treatment of dyskinesias and a very satisfactory safety profile in Phase I studies.

NeuroSearch plans for the initiation in the first half of 2009 of a clinical Phase Ib study in Parkinson patients with L-Dopa induced dyskinesias with a view to determine the tolerability and kinetics of ACR325 in patients and secondary to measure the treatment effect of the product. If satisfactory results are achieved, it is the intention to subsequently initiate a Phase IIb study with a view to selecting optimal doses for Phase III.

ACR343 – Schizophrenia: In clinical Phase I

ACR343 is another dopaminergic stabiliser having demonstrated effect in preclinical models for a number of CNS disorders, whilst leaving the behaviour of normal animals unaffected. Lack of inhibitory effects on normal motor activity is an essential feature of ACR343, implying that impairment of normal functions depending on dopamine transmission such as motion, motivation and reward are not likely to occur. This is considered to be a major advantage over current therapies for a number of diseases, including schizophrenia.

NeuroSearch has evaluated ACR343 in clinical Phase I studies with a highly satisfactory result. Thus ACR343 has shown to have a very attractive profile after oral administration and a very satisfactory safety margin. A Phase II study with ACR343 for the treatment of schizophrenia is expected to be initiated before the end of 2009.

NSD-788 – Anxiety

NSD-788 has demonstrated a unique effect on the monoamine reuptake systems in the brain with primary effect on serotonin and dopamine. Based on studies in preclinical models, NeuroSearch believes that treatment with NSD-788 may potentially show significant advantages over existing drugs for the treatment of anxiety, but also of other CNS disorders including, in particular, various types of depression.

In 2008, NeuroSearch initiated clinical Phase I studies with NSD-788 with the aim of evaluating the compound's safety and tolerability. These studies are progressing according to plan and are expected to be completed in the course of 2009.

Before the initiation of Phase II studies, clinical biomarker studies (PET) are carried out to evaluate the effect of the compound in various areas of the brain.

Q1 Report 2009

Preclinical drug candidates under the collaboration with GSK

NeuroSearch's preclinical pipeline includes five drug candidates which are all covered by the collaboration with GSK. It is expected that two or three of these products can enter into clinical Phase I studies in the course of 2009, leading to milestone payments from GSK.

Affiliates and other equity interests

At 31 March 2009, NeuroSearch held equity interests in the following companies: NeuroSearch Sweden AB (100%), NsExplorer A/S (100%), NeuroScreen ApS (100%) and Poseidon Pharmaceuticals A/S (100%), NsGene A/S (25.9%), Sophion Bioscience A/S (30.1%), ZGene A/S (20.9%). and Atonomics A/S (18.8%), Bavarian Nordic A/S (1.3%) and PainCeptor Pharma Corporation Inc. (2.3%).

NeuroSearch Sweden AB is based in Sweden and PainCeptor Pharma Corporation Inc. is based in Canada. All other affiliated companies are based in Denmark.

Organisation

In March 2009, a reorganising and refocusing of certain drug discovery programmes has taken place as well as an adjustment to current and expected future drug discovery and development alliances. This has resulted in a concentration of resources primarily within CNS discovery programmes and a reduction in the NeuroSearch staff of 20-30 employees.

NeuroSearch has its head office in Ballerup, Denmark, and at 31 March 2009 after the reorganisation a total number of employees of 219.

FINANCIAL REVIEW

The interim report is presented in accordance with IAS 34 as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies. The accounting policies are consistent with those applied in the Annual Report for 2008. The Annual Report 2008 contains the full description of the accounting policies. This interim report is unaudited and unreviewed.

A loss before financials and other shares of results of DKK 96.7 million was posted for the period (a loss of DKK 86.5 million in the same period of 2008). For Q1 2009, a loss after tax of DKK 90.5 million was posted (Q1 2008: a loss of DKK 76.0 million).

Capital resources totalled DKK 550.7 million at 31 March 2009 (DKK 823.5 million at 31 March 2008).

The revenue for the period 1 January to 31 March 2009 of DKK 8.5 million (Q1 2008: DKK 16.6 million) mainly consisted of revenue from the partnership agreements with GSK and Eli Lilly, which will be recognised during the terms of the agreements.

Total costs amounted to DKK 105.2 million (Q1 2008: DKK 103.1 million). Total costs included the calculated costs of DKK 3.9 million (Q1 2008: DKK 5.7 million) of warrants granted in the period from 2005 to 2008. This item has no cash flow effect. Development costs were DKK 39.5 million, which was the same level as in Q1 2008. Development costs in Q1 2009 primarily related to activities with tesofensine (obesity) and ACR16 (Huntington's disease). Research costs and general and administrative cost were at the same level as in Q1 2008.

Other financials amounted to a net income of DKK 3.7 million (Q1 2008: DKK 4.8 million). This included interest expenses relating to mortgages on the company's property totalling DKK 2.3 million (Q1 2008: DKK 1.8 million). The financial element of contingent consideration related to NeuroSearch Sweden AB was an expense of DKK 1.0 million (Q1 2008: Income of DKK 0.3 million). The financial element of contingent consideration has no cash flow effect. Income recognised in relation to other financials was mainly related to a higher interest income from securities and fixed-term deposits.

The Group's investments in property, plant and equipment in Q1 2009 totalled DKK 5.9 million (Q1 2008: DKK 9.7 million). Investments in an expansion of the facility in Ballerup accounted for DKK 3.0 million and the remaining investment of DKK 2.9 million (Q1 2008: DKK 4.0 million) primarily related to investments in equipment.

On 3 March 2009, NeuroSearch issued 530,745 new shares of DKK 20 nominal value. The shares were subscribed by Eli Lilly and Company (Lilly) at a price of DKK 187 per share of a nominal value of DKK 20 each when they entered into a research and development alliance with NeuroSearch.

NEUROSEARCH

Q1 Report 2009

FINANCIAL HIGHLIGHTS AND PER SHARE RATIOS

(DKK million)	GROUP		
	Q1 2009 (3 months)	Q1 2008 (3 months)	2008 (12 months)
Income statement:			
Revenue	8.5	16.6	66.8
Research costs	56.3	53.1	216.8
Development costs	39.5	42.4	176.9
Operating profit/(loss)	(96.7)	(86.5)	(366.0)
Net financials	(2.4)	4.9	(49.9)
Profit/(loss) before taxes	(99.1)	(81.6)	(415.9)
Net profit/(loss)	(90.5)	(76.0)	(382.0)
Total income for the period	(92.3)	(78.2)	(444.5)
Balance sheet:			
Total assets	1,285.7	1.741.2	1,245.8
Cash and cash equivalents, securities and investments	**505.2	794.8	453.4
Equity	844.3	1,111.2	884.1
Investments in property, plant and equipment	5.9	9.7	50.3
Per share ratios (DKK):			
Earnings per share*	(5.69)	(4.94)	(24.47)
Diluted earnings per share	(5.69)	(4.94)	(24.47)
Net asset value	51.88	71.96	53.61
Market price at end of period	69.5	271.50	136.0
Market price/net asset value	1.34	3.77	2.54
Average number of employees	246	230	242

* Per share of DKK 20 nominal value.

** Capital resources, including unused credits, total approximately DKK 550.7 million, of which listed shares account for approximately DKK 11.5 million.

The ratios are stated in accordance with “Recommendations and Financial Ratios” issued by the Danish Society of Financial Analysts.

NEUROSEARCH

Q1 Report 2009

CONDENSED TOTAL INCOME STATEMENT

Income statement (DKK million)	GROUP		
	Q1 2009 (3 months)	Q1 2008 (3 months)	2008 (12 months)
Revenue	8.5	16.6	66.8
Research costs	56.3	53.1	216.8
Development costs	39.5	42.4	176.9
General and administrative costs	9.4	7.6	39.1
Total costs	105.2	103.1	432.8
Operating profit/(loss)	**(96.7)**	**(86.5)**	**(366.0)**
Share of profit/(loss) of associates	(6.0)	0.1	(18.6)
Value adjustment of securities	-	-	(10.2)
Net other financials	3.7	4.8	(21.1)
Tax on income	8.5	5.6	33.9
Net profit/(loss)	**(90.5)**	**(76.0)**	**(382.0)**
Other total income			
Fair value adjustment of available-for-sale financial assets	(1.7)	(3.2)	(15.7)
Exchange rate adjustment of new investment in foreign subsidiary	0.3	1.0	(75.1)
Fair value adjustment of hedge of net investment in foreign subsidiary	(0.4)	-	28.3
Other total income	-	-	-
Total income for the period	**(92.3)**	**(78.2)**	**(444.5)**
Earnings per share, DKK	**(5.69)**	**(4.94)**	**(24.47)**
Diluted earnings per share, DKK	**(5.69)**	**(4.94)**	**(24.47)**

NEUROSEARCH

Q1 Report 2009

CONDENSED BALANCE SHEET

Balance sheet (DKK million)	31 March 2009	31 March 2008	31 December 2008
Intangible assets	559.6	730.2	559.8
Property, plant and equipment	204.0	175.8	202.5
Investments	5.9	21.5	10.7
Receivables	11.0	18.9	19.5
Cash and cash equivalents and securities	505.2	794.8	453.3
Total assets	**1,285.7**	**1,741.2**	**1,245.8**
Equity	844.3	1,111.2	844.1
Non-current liabilities	264.5	365.3	276.2
Current liabilities	176.9	264.7	125.5
Total equity and liabilities	**1,285.7**	**1,741.2**	**1,245.8**

CONDENSED CASH FLOW STATEMENT

Cash flow statement (DKK million)	**GROUP**		
	Q1 2009 (3 months)	Q1 2008 (3 months)	2008 (12 months)
Cash flows from operating activities	(34.1)	(40.0)	(340.0)
Cash flows from investing activities	54.3	(418.2)	(185.2)
Cash flows from financing activities	101.9	4.8	56.3
Net cash flow	122.1	(453.4)	(468.9)
Unrealised gain/(loss) on securities	(11.5)	(0.4)	(20.4)
Net change in cash and cash equivalents	110.6	(453.8)	(489.3)
Cash and cash equivalents at beginning of period	237.1	727.5	727.5
Foreign exchange adjustments of cash and cash equavilens	0	0	(1.1)
Cash and cash equivalents at end of period	347.7	273.7	237.1
Securities at the end of period	141.1	495.0	203.0
Other available-for-sale financial asets at the end of period	11.5	26.1	13.2
Other capital reserves at the end of period*	50.4	28.7	28.2
Capital resources at end of period	**550.7**	**823.5**	**481.5**

* Other capital reserves relate to unused credits etc.

For a breakdown of “cash and cash equivalents” and “securities” as of 31 March 2009 see notes 2 and 3.

Q1 Report 2009

MOVEMENTS IN EQUITY

2009 GROUP **(DKK million)**	Share capital	Share premium	Currency translation reserve	Other re-serves	Retained earnings	Total
Equity at 1 January 2009	314.9	0	(51.5)	5.3	575.5	844.2
Total recognised income for the period	-	-	(0.1)	(1.7)	(90.5)	(92.3)
Right issue	10.6	77.9	-	-	-	88.5
Employee warrant programme	-	-	-	-	3.9	3.9
Transfer	-	(77.9)	-	-	77.9	0
Equity at 31 March 2009	**325.5**	**0**	**(51.6)**	**3.6**	**566.8**	**844.3**

2008 GROUP **(DKK million)**	Share capital	Share premium	Currency translation reserve	Other re-serves	Retained earnings	Total
Equity at 1 January 2008	304.8	0	(4.7)	21.0	800.3	1,121.4
Total recognised income for the period	-	-	1.0	(3.2)	(76.0)	(78.2)
Right issue	3.7	55.5	-	-	-	59.2
Employee warrant programme	0.3	3.0	-	-	5.5	8.8
Transfer	-	(58.5)	-	-	58.5	0
Equity at 31 March 2008	**308.8**	**0**	**(3.7)**	**17.8**	**788.3**	**1,111.2**

Q1 Report 2009

NOTES

1. Accounting estimates and judgments

The preparation of interim consolidated financial statements in accordance with IAS 34 requires the making of estimates and judgments that affect the reporting of assets. liabilities and expenses. The estimates are reviewed on an ongoing basis. Estimates are based on historical experience and on various other assumptions which NeuroSearch believes to be reasonable under the circumstances. However. the actual results may differ significantly from the estimates.

The principles used to make estimates and judgments in the interim consolidated financial statements have been consistently applied in the interim financial statements and the Annual Report 2008. The principles are described in the Annual Report 2008 in note 1 to the financial statements (pages 71).

2. Cash and cash equivalents

Cash and cash equivalents can be specified as follows:

(DKK million)	31 March 2009	31 March 2008	31 December 2008
Money market accounts	93.2	19.6	33.0
Fixed-term deposits	250.6	242.9	200.3
Escrow account regarding building project	3.9	11.2	3.8
Cash and cash equivalents end of period	**347.7**	**273.7**	**237.1**

NeuroSearch is subject to credit risk with respect to bank deposits. The maximum credit risk corresponds to the carrying amount. No credit risk is considered to exist in relation to cash as the counterparties are Nordea and Danske Bank which are covered by the temporary Danish government guarantee.

3. Securities

Securities can be specified as follows:

(DKK million)	31 March 2009	31 March 2008	31 December 2008
Danish mortgage bonds	78.1	440.9	132.5
Unit trusts	63.0	54.1	70.5
Total securities end of period	**141.1**	**495.0**	**203.0**

NEUROSEARCH

Q1 Report 2009

MANAGEMENT'S STATEMENT

The Board of Directors and Executive Management today considered and approved the interim report for the period 1 January to 31 March 2009.

The interim report which is unaudited and unreviewed is presented in accordance with the international accounting standard IAS 34 as adopted by the EU and additional Danish interim financial reporting requirements for listed companies.

We consider the accounting policies to be appropriate and the overall presentation in the interim report to be adequate to the effect that the interim report gives a true and fair view of the Group's assets and liabilities, financial position, results of operations and cash flows for the period 1 January to 31 March 2009.

Furthermore, in our opinion the management's report gives a true and fair statement of the developments in the Group's activities and financial affairs, the results of operations and the Group's financial position as a whole as well as a description of the significant risks and uncertainties the Group faces.

Copenhagen, 29 April 2009

Executive Management

Flemming Pedersen
CEO

_____

Board of Directors

Thomas Hofman-Bang Chairman	Allan Andersen	Torbjörn Bjerke
_____	_____	_____
Anders Ullman	Gerard van Odijk	Torben Skov
_____	_____	_____
Lars Siim Madsen	Mads Peder Gersdorff Korsgaard	
_____	_____	